David Jin
2023 - AVENUE THERAPEUTICS
In 2023, David Jin earned a total compensation of $260K as Interim Chief Financial Officer and Chief Operating Officer at AVENUE THERAPEUTICS.
Compensation breakdown
| Option Awards | $260,000 |
|---|---|
| Total | $260,000 |
Jin received $260K in option awards, accounting for 100% of the total pay in 2023.
Rankings
In 2023, David Jin's compensation ranked 2,496th out of 2,785 executives tracked by ExecPay. In other words, Jin earned more than 10.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,496 out of 2,785 | 10th |
Division Manufacturing | 1,381 out of 1,525 | 9th |
Major group Chemicals And Allied Products | 802 out of 864 | 7th |
Industry group Drugs | 780 out of 827 | 6th |
Industry Pharmaceutical Preparations | 555 out of 592 | 6th |
Source: SEC filing on May 3, 2024.
Jin's colleagues
We found one more compensation record of an executive who worked with David Jin at AVENUE THERAPEUTICS in 2023.
2023
Alexandra MacLean
AVENUE THERAPEUTICS
Chief Executive Officer
News
Avalon GloboCare Corp. CFO Luisa Ingargiola's 2023 pay stays at $350K
August 28, 2024
AVENUE THERAPEUTICS CEO Alexandra MacLean's 2023 pay jumps 304% to $1.2M
May 3, 2024
Fortress Biotech CFO David Jin's 2023 pay jumps 267% to $1.3M
April 5, 2024
Avalon GloboCare Corp. CEO David Jin's 2022 pay stays at $360K
September 8, 2023
Avalon GloboCare Corp. CEO David Jin's 2021 pay falls 64% to $360K
November 21, 2022
Avalon GloboCare Corp. CFO Luisa Ingargiola's 2020 pay slips 20% to $1.1M
December 13, 2021
Avalon GloboCare Corp. CFO Luisa Ingargiola's 2019 pay rises 3% to $1.3M
June 22, 2020
Avalon GloboCare Corp. CFO Luisa Ingargiola's 2018 pay jumps 34% to $1.3M
June 17, 2019